Acetylcholine Receptor Antibodies and Striated Muscle Antibodies Reflexive Panels, and Titin Antibody
Ordering Recommendation
Acceptable reflexive panel for diagnosing myasthenia gravis. Panel contains binding, blocking, and modulating antibodies; titin antibody; and striated muscle antibodies with reflex to titer.
Quantitative Radioimmunoassay/Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Flow Cytometry
1-8 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Plain red top or Serum Separator Tube (SST).  
Specimen Preparation
Transport 1.5 mL serum. (Min. 0.7 mL) Separate serum from cells ASAP or within one hour of collection. Transfer to an ARUP Standard Transport Tube.  
Storage/Transport Temperature
Refrigerated. Frozen is also acceptable.   
Unacceptable Conditions
Plasma. Hemolyzed, lipemic, moderately icteric serum or contaminated specimens.  
Repeated freeze-thaw cycles should be avoided.  
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year  
Reference Interval
Test Number Components Reference Interval
0080009Acetylcholine Receptor Binding Antibody Negative: 0.0-​0.4 nmol/L
Positive:  0.5 nmol/L or greater
0099580Acetylcholine Receptor Blocking Antibody Effective November 18, 2013
Negative: 0-​26% blocking
Indeterminate: 27-​41% blocking
Positive: 42% or greater blocking
0099521Acetylcholine Receptor Modulating Antibody Negative: 0-​45% modulating
Positive: 46% or greater modulating

Effective August 20, 2012
2005636Titin Antibody Effective January 17, 2012
Titin Antibody
Negative 0.00-​0.45 IV
Indeterminate 0.46-​0.71 IV
Positive 0.72 IV or greater
0050746Striated Muscle Antibodies, IgG with Reflex to Titer Less than 1:40
Interpretive Data
Refer to report.

Compliance Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.
If Acetylcholine Receptor Binding Antibody result is greater than 0.4 nmol/L or Acetylcholine Receptor Blocking Antibody result is greater than 26 percent, then Acetylcholine Receptor Modulating Antibody will be added. If Striated Muscle Ab is detected, then a titer will be added. Additional charges apply.
CPT Code(s)
83519; 83516 x2; 86255;  if reflexed, add 83516 and/or 86256
Component Test Code*Component Chart NameLOINC
0050747Striated Muscle Antibodies, IgG Screen49692-7
0080009Acetylcholine Binding Antibody11034-6
0099580Acetylcholine Blocking Antibody42937-3
2005637Titin Antibody 
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • AChR Binding Antibody
  • AChR Antibody
  • Anti-Skeletal Muscle IgG Antibodies
  • Anti-Striated Antibody
  • anti-tintin Ab
  • Muscle (Skeletal) Antibodies
  • Muscle nicotinic Acetylcholine Receptor
  • Myasthenia Gravis Antibodies
  • Myoid Antibody
  • Skeletal Muscle Antibodies
  • Striational Antibodies